Monday, July 20, 2026
Earnings season is here, and it brought the industry its first real answer to the question hanging over 2026: are ACA subsidy expirations actually cutting into procedure volume? Depends who you ask. Intuitive says yes — modestly — and its stock paid for the honesty. Abbott called the whole premise a "flawed assumption" a day earlier. HCA, which sees the patients before the device makers do, warned of softer surgical demand and more uninsured patients. When the market leader in robotics and the industry's most diversified giant read the same quarter differently, that's not noise — that's the demand signal every commercial forecast this year needs to reckon with. Underneath the earnings, the machinery kept moving: a Class I recall, a spine tuck-in, fresh strategic venture money, and a regulatory deadline that hits submissions in less than two weeks.
8 things to watch this week:
1. 🤖 Intuitive’s U.S. procedure growth hits a three-year low — and it’s naming names
Q2 beat on revenue and EPS, but U.S. da Vinci procedure growth slowed to 12% from 14%, and management pointed at two structural culprits: expired ACA enhanced-premium subsidies delaying deferrable surgeries, and GLP-1s pushing bariatric volume down high single digits. The company held its 13.5%–15.5% full-year procedure forecast but guided to the midpoint — and shares dropped double digits, because procedures drive everything downstream in this business model. If insurance-mix softness is real, Intuitive is the canary. Yahoo Finance + 3
MD+DI
2. 🩺 Abbott beats, raises guidance, and shrugs off the ACA worry entirely
Abbott topped Wall Street forecasts and raised full-year adjusted EPS guidance to $5.45–$5.60 — one quarter after cutting it on Exact Sciences dilution, with the March-closed Exact acquisition fueling more than 40% diagnostics growth. The strategic read: diversification is buying Abbott immunity from the exact demand question that just knocked Intuitive down — and management publicly rejected the idea that ACA enrollment declines are materially hurting medtech at all.
MassDevice
3. 🧭 Where does your commercialization actually stand? Two minutes to find out.
Most medical device companies don't stall because the technology is wrong. They stall because the sequencing is — launching before the market's ready, scaling before the evidence lands, chasing the next milestone before the last one is proven. RŌG Health's Commercial Readiness Check is a short diagnostic that maps where your commercialization actually stands right now, across the gaps that quietly derail otherwise strong programs. If you want help closing a gap, it'll point you to the right starting place.
Sponsored by RŌG Health
4. 📉 J&J MedTech growth eases again as Abiomed drags on the quarter
J&J’s device unit posted another quarter of slowing sales growth, with Abiomed weighing on results — a slowdown the company attributed in part to physician response to third-party randomized trial data on Impella. The lesson for every company with a flagship franchise: independent evidence can reprice a market leader’s growth story faster than any competitor can.
Fierce Biotech
5. ⚠️ Medtronic pulls 102 lots of Harmony delivery catheters in Class I recall
Medtronic voluntarily recalled 102 lots of its Harmony delivery catheter system over a distal-tip detachment risk that could require endovascular retrieval or surgery — the FDA’s most serious recall classification, though no serious injuries or deaths had been reported as of mid-May. The valve itself isn’t affected. A reminder that in structural heart, the delivery system carries as much risk exposure as the implant. AOL
Fierce Biotech
6. 🦴 DePuy Synthes buys screwless spine implant maker ahead of its J&J spinout
DePuy acquired Expanding Innovations, whose expandable interbody cages use no screws, on undisclosed terms — strengthening its position in the expandable-cage segment and slotting into the Velys robotic platform as J&J prepares to spin the orthopedics business out. Portfolio-sharpening before a spinout is a familiar playbook: DePuy is building the standalone story it will pitch to public investors.
MedTech Dive
7. 🧠 RapidPulse raises $48M for stroke thrombectomy — with Medtronic co-leading
The Miami-based company closed a Series B for its next-generation aspiration technology for acute ischemic stroke, with Medtronic co-leading alongside TechWald and S3 Ventures. When a strategic co-leads a round in its own core category, read it as an option on future M&A — and a signal of where neurovascular incumbents think the technology curve is bending.
MassDevice
8. 🗓️ FDA hosts Wednesday town hall on human factors guidance — with an August 1 deadline attached
CDRH holds a town hall July 22 on its final guidance covering human factors information in marketing submissions, issued May 29 — and beginning August 1, updated eSTAR templates will prompt manufacturers to identify a Human Factors Submission Category and provide supporting information. If you have a 510(k), De Novo, or PMA in the pipeline, this is the week to get your regulatory team on the same page.
FDA
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.